Vanguard Capital Management
JANX icon

Vanguard Capital Management’s Janux Therapeutics JANX Stock Holding History

Vanguard Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5M Buy
1,857,351
+45,986
+3% +$666K ﹤0.01% 2255
2026
Q1 		$25.2M Buy
+1,811,365
New +$24.8M ﹤0.01% 2211

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management's JANX Position: Q2 2026 in Review

Vanguard Capital Management increased its Janux Therapeutics (JANX) stake by 2.5% in Q2 2026, buying an estimated $666K and bringing the position to 1,857,351 shares worth $28.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2255.

Vanguard Capital Management first reported a position in JANX in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Vanguard Capital Management held 1,857,351 shares of Janux Therapeutics worth $28.5M as of Q2 2026.
  • Vanguard Capital Management bought 45,986 Janux Therapeutics shares in Q2 2026, an estimated $666K.
  • Janux Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2255 holding.
  • Vanguard Capital Management first reported a position in Janux Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.